RubrYc Therapeutics appoints Jean Viret, Ph.D. to its Board of Directors
Thought-leading industry veteran brings two decades of life sciences and biotechnology experience to the company’s Board of Directors
SAN RAMON, CA – November 6, 2018 – RubrYc Therapeutics, a discovery-stage biotherapeutics company, today announced that Jean Viret, Ph.D. has been appointed to the company’s Board of Directors.
"I am thrilled to welcome Dr. Viret to our Board of Directors. Jean is an agile operator and strategist with an impressive track record of financing and collaboration transactions in diagnostic and biotechnology companies," said Isaac Bright, co-founder and CEO of RubrYc Therapeutics. "Dr. Viret’s company-building experiences and broad expertise throughout life science sectors will add value as we build our business."
"I am honored to be joining the RubrYc Board of Directors, as I share their passion to transform the biotherapeutics discovery process through their information-driven platform that aims to speed the discovery of novel therapeutic antibodies and elucidate the functional landscape of targets," said Jean Viret, Ph.D.
Dr. Viret currently serves as Chief Financial Officer for Coherus BioSciences where he completed the initial public offering and a number of subsequent financings for the company. Before joining Coherus as Chief Financial Officer in September 2014, he held the title of CFO at diaDexus, Inc., a cardiovascular diagnostics company, at CareDx, Inc. (formerly XDx, Inc.), a molecular diagnostics company, and at Anesiva, Inc., a biopharmaceutical company. He also worked in finance at Tularik Inc., and business assurance services at PricewaterhouseCoopers LLP.
In addition to a Ph.D. in Plant Molecular Biology from Université Louis Pasteur (Strasbourg), Dr. Viret has a B.S. in Engineering from the Institut National Polytechnique de Lorraine and an M.B.A. from Cornell University. He was a visiting fellow at Harvard University and a postdoctoral fellow at the Massachusetts Institute of Technology.
Isaac Bright, M.D.
RubrYc Therapeutics, Inc.